Poly(ADP-Ribose) Polymerase Inhibitors [MoA]

Poly(ADP-ribose) polymerase inhibitors (PARPi) are selectively active in cells with homologous recombination (HR) deficiency (HRD… (More)

Breast cancer is the most common cancer in women worldwide. Treatment is chosen according to its hormone receptor status and… (More)

 

The majority of pancreatic ductal adenocarcinomas (PDAC) rely on the mRNA stability factor HuR (ELAV-L1) to drive cancer growth… (More)

 

UNLABELLED : High-grade serous ovarian cancer is characterized by genomic instability, with one half of all tumors displaying… (More)

Homologous recombination (HR) and base excision repair (BER) are two of the major DNA-repair pathways. The proteins encoded by… (More)

INTRODUCTION The significant challenge posed by cancer to human healthcare has led to the exploration of new approaches to combat… (More)

Platinum drugs and PARP inhibitors ("PARPis") are considered to be effective in BRCA-associated cancers with impaired DNA repair… (More)

The heterogeneous delivery of drugs in tumors is an established process contributing to variability in treatment outcome. Despite… (More)